deltatrials
Unknown PHASE2 INTERVENTIONAL 3-arm NCT04739202

Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST) (IMMUNOGAST)

An Umbrella Phase 2 Trial to Assess Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent Advanced/Metastatic GASTric Adenocarcinoma Patients

Sponsor: Hospices Civils de Lyon

Conditions Advanced Gastric Carcinoma Gastric Adenocarcinoma Metastatic Adenocarcinoma Metastatic Gastric Cancer
Interventions Atezolizumab + Bevacizumab Atezolizumab + Ipatasertib
Updated 5 times since 2021 Last updated: Mar 26, 2021 Started: Mar 19, 2021 Primary completion: Oct 26, 2023 Completion: Oct 26, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Advanced Gastric Carcinoma and Gastric Adenocarcinoma and is currently ongoing. Hospices Civils de Lyon leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2021 – ~Apr 2021 · 31 days · monthly snapshotNot Yet Recruiting~Apr 2021 – ~Nov 2023 · 31 months · monthly snapshotRecruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotUnknown~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Nov 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  4. Apr 2021 — Nov 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Mar 2021 — Apr 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Hospices Civils de Lyon
Data source: Hospices Civils de Lyon

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations